In Mexico, there are illnesses that kill slowly and silently, taking advantage of the fact that men tend to postpone medical consultations and that health systems do not always prioritize timely detection. Prostate cancer is the most eloquent of these ailments.
Data from Epidemiological Week 21 of 2026—which covers May 24 to 30—confirm it: Yucatán has accumulated 154 reported cases between January and the end of May, four of them recorded during that specific week. Exactly one year ago, the state had 127 cases at the same cutoff. This represents an increase of 21.2 percent in twelve months.
This figure places Yucatán as the seventh state with the most prostate cancer cases in the country, according to the Epidemiological Bulletin of the Ministry of Health (SSA). A year earlier, when it accumulated 127 cases, the entity ranked as the fourth with the highest incidence. This data can be read in two ways: either the growth rate in other entities was higher, or the underreporting in Yucatán was beginning to be corrected. In either case, the trend is worrying.
National Overview
Nationally, Mexico confirmed 153 new cases during Week 21 of 2026, bringing the total to 3,126 patients so far this year, a jump of 22.5 percent compared to the 2,551 cases during the same period in 2025.
Jalisco is the entity with the most confirmed cases in the country: 763 accumulated up to May 30, 43 of them detected in Week 21. This represents a growth of 9.3 percent in one year—698 cases in W21 of 2025—which, while significant, was lower than that recorded in Yucatán.
On the other end of the spectrum, Quintana Roo is the entity with the lowest incidence in the country: only two confirmed cases at the close of May, with a 75 percent drop compared to the eight cases from a year ago. Campeche, for its part, totals 15 cases—three fewer than in 2025—and did not report any new cases in Week 21, positioning itself as the fifth state with the lowest national incidence.
As a whole, the three states of the Yucatán Peninsula—Yucatán, Campeche, and Quintana Roo—sum up 171 men with a confirmed diagnosis of prostate cancer between January 1 and May 30, 2026. The disparity among the three entities is notable: while Yucatán concentrates 90 percent of the peninsular cases, Quintana Roo barely registers two patients. Differences in diagnostic capacity, access to specialized services, and screening coverage between states partly explain these gaps.
Second Cause of Male Death
The incidence data is eloquent, but the mortality data is what provides the true scale of the problem. The National Institute of Statistics and Geography (Inegi) reports that 128 men died from prostate cancer in Yucatán in 2024, 20 more than the 108 who died in 2023, an increase of 18.5 percent in a single year. This figure makes this cancer the second cause of male death in the state, surpassed only by heart diseases, which claimed 2,180 lives in the same year.
To dimension what those numbers mean: in Yucatán, an average of one man dies from prostate cancer every three days. And this is without considering cases that might be underreported or classified under other causes. Inegi further specifies that more than 60 percent of diagnoses are concentrated in men over 65 years of age, connecting the problem to the progressive aging of the Yucatecan population pyramid.
Factors in Mortality
The landscape in the rest of the Peninsula draws different epidemiological profiles. In Campeche, prostate cancer is the third cause of male mortality, with 53 deaths in 2024, behind heart ailments (854 deaths) and diabetes (334). In Quintana Roo, it occupies fifth place with 59 deaths in the same year, surpassed by heart diseases (838), diabetes (596), assaults or homicidios (525), and accidents (482).
Nationally, 7,420 men lost their lives to this cancer in 2024, including 236 who resided in one of the states of the Peninsula, meaning 3.1 percent of the national total.
Paradoxically, in terms of mortality, the Peninsula presents relatively low figures compared to the rest of the country: Campeche is the state with the lowest mortality, Quintana Roo is the fifth lowest, and Yucatán is the tenth lowest. This apparent contradiction—high incidence, relatively low mortality—can respond to different factors: a smaller total population, early detection, or variations in the quality of death registration. The State of Mexico tops the national mortality list, with 830 deaths in 2024.
The Key That Remains Pending
The grand consensus among oncourologists and health authorities is that prostate cancer detected in early stages has survival rates close to one hundred percent. The problem is that most cases are diagnosed when the disease has already advanced, partly because its initial symptoms are subtle or easily attributable to other conditions.
The Ministry of Health recommends that men from the age of 45 undergo detection studies—or from 40 if they have a family history—but adherence to this recommendation remains low.
The Mexican Social Security Institute (IMSS) establishes that the comprehensive detection of prostate cancer includes three fundamental actions: a prostate symptom questionnaire, a digital rectal exam, and the measurement of the prostate-specific antigen (PSA) in blood. This combination allows for the identification of abnormalities even when the patient does not present discomfort.
The Warning Signs
The warning signs that any man should know include: a weak or interrupted urine flow, difficulty starting urination, a burning sensation when urinating, a frequent need to go to the bathroom—especially at night—, pain in the pelvic area, lower back, or hips, and the presence of blood in the urine or semen. None of these symptoms is exclusive to prostate cancer, but all justify an immediate medical consultation.
The Pan American Health Organization (PAHO) notes that prostate cancer is the most frequently diagnosed cancer among men in Latin America, representing 21.8 percent of all male cancers in the region.
In Yucatán, where prostate cancer already kills more men than stomach cancer, liver cancer, or any other malignant tumor, and where reported cases grew 21.2 percent in a single year, early detection ceases to be a general recommendation to become a concrete urgency.
Each week that passes without a timely diagnosis can radically change the prognosis. Epidemiological Week 21 of 2026 registered four new cases in the state. The question is how many more are not being counted.
Source: poresto
